NCT04069143

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

An Open-Label Study to Evaluate the Safety, Tolerability, Kinetics, and Repeatability of the Novel Lysophosphatidic Acid Receptor 1 (LPA1) Positron Emission Tomography (PET) Ligand 18F-BMS-986327

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the safety, tolerability, kinetics and test-retest repeatability of the novel LPA1 positron emission tomography (PET) ligand 18F-BMS-986327 in healthy participants and participants with idiopathic pulmonary fibrosis (IPF).

Conditions

• Healthy Participants
• Idiopathic Pulmonary Fibrosis (IPF)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	18F-BMS-986327	Imaging Agent

Timeline

• Start date: 2019-10-01
• Primary completion: 2022-07-12
• Completion: 2022-07-12
• First posted: 2019-08-28
• Last updated: 2023-03-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study